Nyxoah (NASDAQ:NYXH) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Nyxoah (NASDAQ:NYXH) posted its earnings results on Thursday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04, FiscalAI reports. The firm had revenue of $10.39 million during the quarter, compared to analyst estimates of $11.00 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%.

Here are the key takeaways from Nyxoah’s conference call:

• Nyxoah cut its 2026 revenue guidance to €33 million–€35 million, citing a U.S. launch ramp more in line with historical adoption patterns, despite strong sequential growth in the quarter.
• U.S. revenue rose 29% sequentially to €6.7 million, while the company trained 80 surgeons and activated 53 accounts in Q3; it plans to prioritize deeper utilization at existing accounts.
• The ACCCESS study met its primary efficacy and safety endpoints in patients with complete concentric collapse (CCC), and Nyxoah submitted an FDA supplement seeking to expand Genio’s U.S. indication to this group, which the company estimates represents about one in four patients evaluated for the therapy.
• Gross margin improved to 63.1% from 60.5% a year earlier, and the company reported a narrower operating loss. It also cited higher 2027 CMS facility reimbursement rates for Genio procedures.
• Cash and financial assets fell to €77.1 million at September 30 from €97.8 million at June 30, underscoring the company’s ongoing cash use as it invests in its commercial launch.

Nyxoah Stock Performance

Shares of NASDAQ NYXH traded up $0.03 during midday trading on Friday, reaching $0.85. 262,088 shares of the company traded hands, compared to its average volume of 235,695. Nyxoah has a 52 week low of $0.80 and a 52 week high of $5.92. The stock has a 50-day moving average price of $1.27 and a 200 day moving average price of $2.42. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.38 and a quick ratio of 2.31. The company has a market cap of $32.78 million, a price-to-earnings ratio of -0.43 and a beta of 1.80.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on NYXH shares. Weiss Ratings restated a “sell (e+)” rating on shares of Nyxoah in a research note on Wednesday, August 19th. Robert W. Baird set a $2.31 price target on Nyxoah in a report on Thursday, August 6th. Cantor Fitzgerald reduced their price objective on Nyxoah to $3.00 and set an “overweight” rating for the company in a research report on Tuesday, October 27th. Raymond James Financial set a $3.00 price objective on Nyxoah in a report on Tuesday, October 27th. Finally, Wall Street Zen upgraded Nyxoah from a “sell” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.55.

About Nyxoah

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.